Cellectar Biosciences (United States)

Recent papers from Cellectar Biosciences (United States)

1. Sex Differences in Urinary Extracellular Vesicles Originating from the Genitourinary System in Health and DiseaseAJP Renal Physiology · 2026
2. A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaCancers · 2026
3. Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety.Journal of Clinical Oncology · 2026
4. From mono- to multi-cellular in vitro models: reconstructing colorectal cancer complexity for translational and personalized applicationsFrontiers in Cell and Developmental Biology · 2026
5. Advancements in extracellular vesicle researchExtracellular Vesicle · 2026
6. Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-upBlood Cancer Journal · 2026
7. Calibration of Flow Cytometers Enables Reproducible Measurements of Extracellular Vesicle Concentrations and Reference Range EstablishmentJournal of Extracellular Vesicles · 2025
8. Preclinical Evaluation of a Pilocarpine–(R)-Lipoic Acid Eye Drop for PresbyopiaTranslational Vision Science & Technology · 2025
9. Abstract B032: Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-ConjugateCancer Research · 2025
10. Abstract A019: Precision radiotherapy for incurable brain tumors: Phase 1b dose & regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma, interim data assessmentCancer Research · 2025
11. Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-upBlood Cancer Journal · 2025
12. Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion studyEBioMedicine · 2024
13. A compendium of single extracellular vesicle flow cytometryJournal of Extracellular Vesicles · 2023
14. Iopofosine I-131 treatment in late line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy2022
15. Rigor and reproducibility: status and challenges for single vesicle analysisExtracellular Vesicles and Circulating Nucleic Acids · 2022
16. Increased Internal Porosity and Surface Area of Hydroxyapatite Accelerates Healing and Compensates for Low Bone Marrow Mesenchymal Stem Cell Concentrations in Critically-Sized Bone DefectsApplied Sciences · 2018
17. CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast CancerCancer Biotherapy and Radiopharmaceuticals · 2018
18. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood–Brain Barrier ModelMolecular Pharmaceutics · 2016
19. Editorial: Defining the Risk of Small Polyps: Potential Value of CTCThe American Journal of Gastroenterology · 2015
20. A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid MalignanciesCancer Investigation · 2015